CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

Oncoimmunology. 2016 Dec 23;6(2):e1273302. doi: 10.1080/2162402X.2016.1273302. eCollection 2017.


PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.

Keywords: Adoptive T-cell therapy; PD-1 blockade; breast cancer; immunosuppression; lung cancer; mesothelioma; tumor microenvironment.